SAGE 217

Drug Profile

SAGE 217

Alternative Names: SAGE-217

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SAGE Therapeutics
  • Class Antiepileptic drugs; Small molecules
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Seizures

Highest Development Phases

  • Phase II Essential tremor; Major depressive disorder; Parkinson's disease; Postnatal depression
  • Phase I Seizures
  • Preclinical Dyskinesias

Most Recent Events

  • 18 Sep 2017 Sage Therapeutics plans a phase I trial in Insomnia (In volunteers) in USA (PO,Capsules) in September 2017 (NCT03284931)
  • 07 Jun 2017 Adverse events and pharmacodynamics data from a single-ascending dose phase I trial (In volunteers) presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 18 May 2017 SAGE 217 receives Fast Track designation for Major depressive disorder [PO] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top